Protein Kinase Inhibitors: all 15,278 studies that test it

Page 119 of 153. Open to participants first (2,558), then studies with results posted, then the rest; newest registration first within each.

• Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab TherapyTerminatedNCT02205398Phase 1
• The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CMLCompletedNCT02204644Phase 3
• Pazopanib Vs. Pazopanib Plus GemcitabineActive, not recruitingNCT02203760Phase 2
• Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic MelanomaStatus unknownNCT02202200Phase 1/2
• Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)Active, not recruitingNCT02201992Phase 3
• Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)TerminatedNCT02200848Phase 1
• Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV MelanomaTerminatedNCT02200562Phase 1
• A Pharmacokinetic Study to Assess the Influence of P-glycoprotein Inhibition and Simultaneous CYP3A4 and P-glycoprotein Induction on E7080 Pharmacokinetics Following Single Dose Oral Administration of 24 mg E7080 to Healthy VolunteersCompletedNCT02199392Phase 1
• A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy SubjectsCompletedNCT02199379Phase 1
• Regorafenib + Panitumumab for Colorectal CancersTerminatedNCT02199223Phase 1
• Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)TerminatedNCT02198482Phase 2
• Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has SpreadActive, not recruitingNCT02196181Phase 2
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruitingNCT02194738Not applicable
• Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung CancerCompletedNCT02194049Phase 1
• A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.CompletedNCT02193633Phase 1
• Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)Active, not recruitingNCT02193282Phase 3
• An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) MutationsTerminatedNCT02192697Phase 1/2
• Absolute Bioavailability Of BosutinibCompletedNCT02192294Phase 1
• Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular CarcinomaCompletedNCT02191878Phase 1/2
• Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung CancerStatus unknownNCT02191059Phase 2
• Study of CLR457 Administered Orally in Adult Patients With Advanced Solid MalignanciesTerminatedNCT02189174Phase 1
• Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal CancerCompletedNCT02188264Phase 1
• Deciphering Afatinib Response and Resistance With INtratumour HeterogeneityCompletedNCT02183883Phase 2
• EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung CancerCompletedNCT02183870Phase 2
• Safety and Tolerability Study of BIBF 1120 as Intravenous Infusion and Absolute Bioavailability of BIBF 1120 as Soft Gelatine Capsule in Healthy SubjectsCompletedNCT02182258Phase 1
• Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological MalignanciesCompletedNCT02182245Phase 1
• Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate CancerCompletedNCT02182219Phase 1
• An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid TumoursCompletedNCT02182206Phase 1
• Safety and Relative Bioavailability of BIBF 1120 Soft Gelatine Capsules Charge 1, BIBF 1120 Soft Gelatine Capsules Charge 2 and BIBF 1120 Drinking Solution in Healthy Male VolunteersCompletedNCT02182193Phase 1
• Metabolism and Pharmacokinetics of [14C]-BIBF 1120 in Healthy Male VolunteersCompletedNCT02182154Phase 1
• An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02182141Phase 1
• A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid TumoursCompletedNCT02182128Phase 1
• Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung CancerCompletedNCT02182102Phase 1
• Pharmacokinetics/Bioavailability of BIBF 1120 Administered to Healthy Male VolunteersCompletedNCT02182076Phase 1
• A Study With BIBF 1120 in Patients With Hormone Refractory Prostate CancerCompletedNCT02182063Phase 2
• Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung CancerCompletedNCT02182050Phase 2
• Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02181660Phase 1
• A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFRTerminatedNCT02178397Phase 3
• Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform NeurofibromasTerminatedNCT02177825Phase 2
• Sirolimus Prophylaxis for aGVHD in TME SCIDWithdrawnNCT02177760Phase 2
• Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma PatientsTerminatedNCT02177682Phase 1
• Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus BevacizumabTerminatedNCT02175654Phase 2
• A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical InterventionStatus unknownNCT02174991Phase 2
• An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two YearsTerminatedNCT02174445Phase 3
• Safety and Tolerability of 4 Different Dosage Strengths of BIBW 2992 Tablets to Healthy Male VolunteersCompletedNCT02171767Phase 1
• Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid TumorsCompletedNCT02171741Phase 1
• Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid TumorsCompletedNCT02171728Phase 1
• BIBW 2992 Administered as Tablet (Final Formulation) Compared to BIBW 2992 Drinking Solution and BIBW 2992 Tablet (Trial Formulation II) in Healthy Male VolunteersCompletedNCT02171715Phase 1
• Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid TumoursCompletedNCT02171702Phase 1
• Metabolism and Pharmacokinetics of [14C]- BIBW 2992 MA2 in Healthy Male VolunteersCompletedNCT02171689Phase 1
• BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid TumorsCompletedNCT02171676Phase 1
• Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid TumorsCompletedNCT02171663Phase 1
• BIBW 2992 in Patients With Advanced Solid TumorsCompletedNCT02171650Phase 1
• Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid TumorsCompletedNCT02171637Phase 1
• Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT02169180Phase 2
• Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast CancerCompletedNCT02167854Phase 1
• VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid TumorsCompletedNCT02164838Phase 1
• JAK-inhibition in Recurrent Classical Hodgkin LymphomaCompletedNCT02164500Phase 2
• Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma PatientsCompletedNCT02164006Phase 1
• AStudy to Evaluate the Bioavailability of PF 04965842 in Healthy SubjectsCompletedNCT02163161Phase 1
• Multiple Ascending Dose Study of GLPG0634 in Japanese and Caucasian Healthy SubjectsCompletedNCT02162355Phase 1
• Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver ImpairmentCompletedNCT02161770Phase 1
• RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung CancerTerminatedNCT02161419Phase 2
• Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic MalignanciesCompletedNCT02160951Phase 1
• First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid TumorsCompletedNCT02160106Phase 1
• Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by SurgeryActive, not recruitingNCT02160015Phase 1
• Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell LymphomaActive, not recruitingNCT02159755Phase 1
• M6620 First in Human StudyCompletedNCT02157792Phase 1
• Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic LeukemiaActive, not recruitingNCT02157324Phase 1
• Copanlisib Pharmacodynamic StudyCompletedNCT02155582Phase 1
• BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic CancerCompletedNCT02155088Phase 1
• Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.CompletedNCT02154776Phase 1
• Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic CancerCompletedNCT02154737Phase 1
• A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the BodyCompletedNCT02154646Phase 1
• Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive PatientsCompletedNCT02152943Phase 1
• A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based ChemotherapyWithdrawnNCT02152059Phase 2
• Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung CancerStatus unknownNCT02151721Phase 1
• INCB047986 in Rheumatoid ArthritisTerminatedNCT02151474Phase 2
• Safety, Tolerability and Pharmacokinetics of DCBCI0901 in Patients With Advanced Solid TumorTerminatedNCT02151357Phase 1
• Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic ImpairmentCompletedNCT02150733Phase 1
• Combination of Chemotherapy and Gefitinib as First-line TreatmentCompletedNCT02148380Not applicable
• A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung AdenocarcinomaStatus unknownNCT02146118Phase 2
• An Open Label, Single Arm, Multicenter Phase II Study of BYL719 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy.Status unknownNCT02145312Phase 2
• Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot StudyCompletedNCT02145143Early Phase 1
• Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple MyelomaCompletedNCT02144038Phase 1
• Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT02143401Phase 1
• Study of Dabrafenib, Trametinib and Metformin for Melanoma PatientsWithdrawnNCT02143050Phase 1/2
• Investigation Of The Metabolism, And Excretion Of [14c]-PF-05212384 In Healthy Male VolunteersCompletedNCT02142920Phase 1
• A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K in Healthy SubjectsCompletedNCT02141425Phase 1
• UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered TrametinibWithdrawnNCT02140840Phase 2
• Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLCStatus unknownNCT02140333Phase 3
• Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous PaclitaxelTerminatedNCT02138812Phase 1
• A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type MelanomaCompletedNCT02138292Phase 1
• Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular HypertensionCompletedNCT02136940Phase 2
• A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule FormulationCompletedNCT02136524Phase 1
• The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted RecipientsCompletedNCT02134899Phase 3
• Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV InfectionTerminatedNCT02134886Phase 1
• Belatacept for Renal Transplant Recipients With Delayed Graft FunctionTerminatedNCT02134288Early Phase 1
• Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid TumorsTerminatedNCT02134067Phase 1
• Sapanisertib Before and After Surgery in Treating Patients With Recurrent GlioblastomaTerminatedNCT02133183Phase 1

← Protein Kinase Inhibitors overview